<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923193</url>
  </required_header>
  <id_info>
    <org_study_id>CP 60892</org_study_id>
    <nct_id>NCT02923193</nct_id>
  </id_info>
  <brief_title>Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)</brief_title>
  <official_title>Randomized Study of the Shockwave Medical Peripheral Lithoplasty® System Used in Combination With DCB Versus Standard Balloon Angioplasty Used in Combination With DCB to Treat Moderate and Severely Calcified Femoropopliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shockwave Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shockwave Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shockwave Medical Inc. intends to conduct a prospective, multi-center, single blind,
      randomized (1:1) study of Lithoplasty treatment used in combination with DCB versus standard
      balloon angioplasty used in combination with DCB to treat moderate and severely calcified
      femoropopliteal arteries. Assuming that roughly 15% of the subjects will be
      lost-to-follow-up, a total of 334 subjects (167 per treatment arm) will be enrolled in the
      study.

      In addition to the randomized study, an observational study of subjects who do not meet the
      inclusion/exclusion criteria for the randomized study will be conducted. The objective of the
      observational study is to assess the real-world acute performance of the Shockwave Medical
      Peripheral Lithoplasty System in the treatment of calcified, stenotic, peripheral arteries.

      The observational study is a prospective, multi-center, single arm observational study for
      subjects who do not meet the inclusion/exclusion criteria of the randomized study.

      A maximum of 250 subjects at the same 50 sites will be enrolled in the observational study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shockwave Medical Inc. intends to conduct a prospective, multi-center, single blind,
      randomized (1:1) study of Lithoplasty treatment used in combination with DCB versus standard
      balloon angioplasty used in combination with DCB to treat moderate and severely calcified
      femoropopliteal arteries. The Shockwave Medical Peripheral Lithoplasty System is indicated
      for lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral
      arteries in patients who are candidates for percutaneous therapy. Up to 334 subjects at 45
      sites in Europe, the United States and New Zealand.

      Subjects will be followed through discharge, 30 days, and 6, 12 and 24 months. DUS
      assessments will be completed at 12 and 24 months.

      Procedural success defined as residual stenosis &lt;30% prior to DCB or stenting by angiographic
      core lab.

      Subjects who do not meet the randomized study inclusion and exclusion criteria, but meet the
      inclusion and exclusion criteria for the observational study may be enrolled in the
      observational study. The objective of the observational study is to assess the real-world
      acute performance of the Shockwave Medical Lithoplasty System in the treatment of calcified,
      stenotic, peripheral arteries.The observational study is a prospective, multi-center, single
      arm observational study for subjects who do not meet the inclusion/exclusion criteria of the
      randomized study. A maximum of 250 subjects at the same 50 sites will be enrolled in the
      observational study. Procedural success defined as residual stenosis &lt;30% prior to DCB or
      stenting by angiographic core lab. Enrollment in the observational study is anticipated to
      last approximately 16 months. Subjects in the observational study will be followed through
      hospital discharge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural success defined as residual stenosis &lt;30% prior to DCB or stenting by angiographic core lab.</measure>
    <time_frame>Periprocedural</time_frame>
    <description>Procedural success defined as residual stenosis &lt;30% prior to DCB or stenting by angiographic core lab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary patency defined as freedom from clinically-driven target lesion revascularization (TLR) and freedom from restenosis determined by duplex ultrasound or angiogram &gt;50% stenosis.</measure>
    <time_frame>Peri-Procedural</time_frame>
    <description>acute PTA failure requiring a stent at any time during the index procedure will be counted as a TLR at day 0, and loss of primary patency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of new-onset Major Adverse Events (MAEs)</measure>
    <time_frame>Within 30 days, 6, 12 and 24 months post procedure</time_frame>
    <description>Need for emergency surgical revascularization of target limb
Unplanned target limb major amputation (above the ankle)
Symptomatic thrombus or distal emboli that require surgical, mechanical or pharmacologic means to improve flow and extend hospitalization
Perforations that require an intervention, including bail-out stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
    <description>defined as freedom from clinically-driven target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success ABI</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
    <description>defined as ankle-brachial index ABI reported as change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success Rutherford Category</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
    <description>defined as Rutherford Category reported as change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success Quality of Life</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
    <description>defined by Quality of Life assessed by EQ5D questionnaire reported as change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Lithoplasty System followed by DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medtronic IN.PACT (DCB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shockwave Lithoplasty® Peripheral Lithoplasty System</intervention_name>
    <description>The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.</description>
    <arm_group_label>Lithoplasty System followed by DCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medtronic IN.PACT (DCB)</intervention_name>
    <description>The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.</description>
    <arm_group_label>Lithoplasty System followed by DCB</arm_group_label>
    <arm_group_label>Medtronic IN.PACT (DCB)</arm_group_label>
    <other_name>drug coated balloon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is able and willing to comply with all assessments in the study.

          2. Subject or subject's legal representative have been informed of the nature of the
             study, agrees to participate and has signed the approved consent form.

          3. Age of subject is &gt; 18.

          4. Rutherford Clinical Category 2, 3, or 4 of the target limb.

          5. Estimated life expectancy &gt;1 year.

          6. Subject is a suitable candidate for angiography and endovascular intervention in the
             opinion of the investigator or per hospital guideline.

          7. Subject is intended to undergo treatment with Lithoplasty followed by DCB or DCB with
             standard balloon pre-dilatation.

             Angiographic Inclusion Criteria

          8. Target lesion that is located in a native, de novo superficial femoral artery (SFA) or
             popliteal artery (popliteal

          9. Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate.

         10. Target lesion is ≥70% stenosis by investigator via visual estimate.

         11. Target lesion length is 50-180mm for lesions 70-99% stenosed. Target lesion can be all
             or part of the 180mm treated zone.

         12. Chronic total occlusion lesion length is ≤100mm.

         13. Subject has at least one patent tibial vessel on the target leg with runoff to the
             foot, defined as no stenosis &gt;50%.

         14. Calcification is at least moderate defined as presence of fluoroscopic evidence of
             calcification: 1) on parallel sides of the vessel and 2) extending &gt; 50% the length of
             the lesion.

        Exclusion Criteria:

        Rutherford Clinical Category 0, 1, 5 and 6. 2. Subject has active infection requiring
        antibiotic therapy. 3. Planned target limb major amputation (above the ankle). 4. History
        of prior endovascular or surgical procedure on the index limb within the past 30 days or
        planned within 30 days of the index procedure.

        5. Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with
        platelet count less than 100,000/microliter.

        6. Subject in whom antiplatelet or anticoagulant therapy is contraindicated. 7. Subject has
        known allergy to contrast agents or medications used to perform endovascular intervention
        that cannot be adequately pre-treated.

        8. Subject has known allergy to urethane, nylon, or silicone. 9. Myocardial infarction
        within 60 days prior to enrollment. 10.History of stroke within 60 days prior to
        enrollment. 11.History of thrombolytic therapy within two weeks of enrollment. 12.Subject
        has acute or chronic renal disease (e.g., as measured by a serum creatinine of &gt;2.5 mg/dL
        or &gt;220 umol/L), or on dialysis.

        13.Subject is pregnant or nursing. 14.Subject is participating in another research study
        involving an investigational agent (pharmaceutical, biologic, or medical device) that has
        not reached the primary endpoint.

        15.Subject has other medical, social or psychological problems that, in the opinion of the
        investigator, preclude them from receiving this treatment, and the procedures and
        evaluations pre- and post-treatment.

        16.The use of specialty balloons, re-entry or atherectomy devices.

        Angiographic Exclusion Criteria 17.In-stent restenosis within the target zone. 18.Lesions
        extending from common femoral to superficial femoral artery or within 10 mm of the ostium
        of the anterior tibial artery.

        19.Evidence of aneurysm or thrombus in target vessel. 20.No calcium or mild calcium in the
        target lesion. 21.Target lesion within native or synthetic vessel grafts. 22.Subject has
        significant stenosis (&gt;50% stenosis) or occlusion of inflow tract before target treatment
        zone (e.g. iliac or common femoral) not successfully treated.

        23.Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to
        target site at the time of the index procedure.

        24.Unable to pass the guidewire across the target lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Tepe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut für Diagnostische und Interventionelle Radiologie &amp; RoMed Klinikum Rosenheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William A Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Main Line Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pojai Phattanagosai</last_name>
    <phone>1 510 279 4262</phone>
    <email>pphattanagosai@shockwavemedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abrazo Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Ames</last_name>
      <email>pames@abrazohealth.com</email>
    </contact>
    <investigator>
      <last_name>Venkatesh Ramaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Catherine Falkner</last_name>
      <phone>501-748-8421</phone>
      <email>marycatherine.falkner@arheart.com</email>
    </contact>
    <investigator>
      <last_name>Ian Cawich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Vesom</last_name>
      <email>nvesom@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Dake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver VA Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caitlin Kielhorn</last_name>
      <phone>303-399-8020</phone>
      <phone_ext>4019</phone_ext>
      <email>caitlin.kielhorn@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Ehrin Armstrong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCHealth Northern Colorado</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Jaskowiak</last_name>
      <phone>970-624-1688</phone>
      <email>adam.jaskowiak@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>William Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Shaddinger, RN</last_name>
      <email>dawn.shaddinger@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Carlos Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Cardiovascular Research Network @ Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suman Singh</last_name>
      <email>Suman.Singh@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Tareq Massimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute, Inc.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Knap</last_name>
      <phone>850-431-5024</phone>
      <email>patty.knap@tmh.org</email>
    </contact>
    <investigator>
      <last_name>William Dixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Patrick</last_name>
      <email>donna.patrick@nghs.com</email>
    </contact>
    <investigator>
      <last_name>Jeff Marshall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>April Levesque</last_name>
      <email>april.levesque@amitahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jack Chamberlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals Corporation</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Elder, RN</last_name>
      <email>Lea.elder@advocatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Mark Goodwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Lowrance</last_name>
      <phone>217-492-9100</phone>
      <phone_ext>126</phone_ext>
      <email>mlowrance@prairieresearch.com</email>
    </contact>
    <investigator>
      <last_name>Nilesh J. Goswami, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Shammas</last_name>
      <email>shammasw@mcrfmd.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Shammas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Steward St. Elizabeth's Medical Center</name>
      <address>
        <city>Brighton</city>
        <state>Maine</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Pustelnikas</last_name>
      <email>amanda.pustelnikas@steward.org</email>
    </contact>
    <investigator>
      <last_name>Lawrence Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension / St. John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynn Boomer</last_name>
      <email>lynn.boomer@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Kirit Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension / St. John Providence</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Kelly</last_name>
      <phone>248-849-3369</phone>
      <email>jean.kelly@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Alexander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha Jones</last_name>
      <email>mrjones@nmhs.net</email>
    </contact>
    <investigator>
      <last_name>Barry Bertolet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cardiovascular</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Miller</last_name>
      <email>m2miller@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Steven Laster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Dewey</last_name>
      <email>deweyl@deborah.org</email>
    </contact>
    <investigator>
      <last_name>Vince Varghese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Bird</last_name>
      <email>amya@nmhi.com</email>
    </contact>
    <investigator>
      <last_name>Steve Henao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai West</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruslan Mull</last_name>
      <phone>212-523-8353</phone>
      <email>ruslan.mull@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>James McKinsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gallo</last_name>
      <email>michael.gallo@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Prakash Krishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Dalton</last_name>
      <email>keb2114@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Sahil Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Morton</last_name>
      <email>cmorton@nchvresearch.com</email>
    </contact>
    <investigator>
      <last_name>George Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WakeMed Heart Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Norton</last_name>
      <email>Rnorton@WakeMed.org</email>
    </contact>
    <investigator>
      <last_name>Siddhartha Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Belcher</last_name>
      <email>christina.belcher@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>John A Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PinnacleHealth Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Meise</last_name>
      <email>GMeise@PINNACLEHEALTH.org</email>
    </contact>
    <investigator>
      <last_name>William Bachinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Einstein Medical Center Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinnari Murthy</last_name>
      <email>murthyK@einstein.edu</email>
    </contact>
    <investigator>
      <last_name>Sean Janzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Cardiovascular Institute</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Meise</last_name>
      <email>GMeise@PINNACLEHEALTH.org</email>
    </contact>
    <investigator>
      <last_name>William Bachinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Heart Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Marie Chikowski</last_name>
      <email>ChikowskiA@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Sarang Mangalmurti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Felix, RN</last_name>
      <email>lfelix@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Peter Soukas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vascular Associates</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Collette Springman</last_name>
      <phone>605-328-1384</phone>
      <email>collette.springman@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Chad Laurich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freda Campbell</last_name>
      <phone>423-230-5641</phone>
      <email>freda.campbell@wellmont.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Metzger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennova Healthcare - Turkey Creek Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Polk, RN</last_name>
      <phone>865-218-7535</phone>
      <email>beth.polk@tennova.com</email>
    </contact>
    <investigator>
      <last_name>Malcolm Foster III, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. David's Heart and Vascular dba Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bejamin Vouk</last_name>
      <email>Benjamin.Vouk@hcahealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Roger Gammon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Enriquez</last_name>
      <phone>713-798-7537</phone>
      <email>ana.enriquez@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Miguel Montero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabi Platzer</last_name>
      <email>Gabriele.Platzer@klinikum-graz.at</email>
    </contact>
    <investigator>
      <last_name>Marianne Brodmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinen-Hospital</name>
      <address>
        <city>Arnsberg</city>
        <zip>59759</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Mueller</last_name>
      <email>si.mueller@studynurse-si.de</email>
    </contact>
    <investigator>
      <last_name>Michael Lichtenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg &amp; Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Verena Zähringer</last_name>
      <email>verena.zaehringer@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Zeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sankt Gertrauden-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heike Bütow</last_name>
      <email>Heike.Buetow@sankt-gertrauden.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Langhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Center for Cardiovascular Interventions (ICCI)</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Streuber</last_name>
      <email>tanja.streuber@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Nikos Werner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiter Sektion Angiologie</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Streuber</last_name>
      <email>tanja.streuber@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Nadjib Schahab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik II</name>
      <address>
        <city>Bruchsal</city>
        <zip>76646</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Scherer-Stolz</last_name>
      <email>manuela.scherer-stolz@kliniken-lk.de</email>
    </contact>
    <investigator>
      <last_name>Martin Andrassy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Gefäßmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Fentroß</last_name>
      <email>n.fentross@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Hans Krankenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AoR Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine Brunotte</last_name>
      <email>janine.brunotte@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Dierk Scheinert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bärbel Kaesberger</last_name>
      <email>j-balzer@kkmainz.de</email>
    </contact>
    <investigator>
      <last_name>John O Balzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Franziskus Hospital</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Hericks</last_name>
      <email>christiane.hericks@sfh-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Arne Schwindt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Mühlheim an der Ruhr</name>
      <address>
        <city>Mülheim</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dinter</last_name>
      <email>jennifer.dinter@evkmh.de</email>
    </contact>
    <investigator>
      <last_name>Claus Nolte-Ernsting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Rinser</last_name>
      <email>erika.rinser@ro-med.de</email>
    </contact>
    <investigator>
      <last_name>Gunnar Tepe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Katae</last_name>
      <email>DKatae@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Andrew Holden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

